ABUS Arbutus Biopharma Corp Total Asset Value of Company

ABUS (Arbutus) - company brandmark

Arbutus Biopharma (ABUS) functions as a patent hub in the field of hepatitis B therapy, benefiting from long-term licensing royalties. This chart of the company's total assets is fixed at 188.65. The business relies on owning rights for drug delivery via lipid nanoparticles, ensuring a steady stream of royalties. The company is currently investing in clinical trials, which temporarily limits profits due to high expenses until products are brought to market.

ABUS (Arbutus Biopharma) Company Total Assets history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Arbutus (ABUS)

- current quotes and average value forecast:
Market Chart arbutusbio.com|ABUS - Price Target Chart
- market capitalization data:
Market Valuation Tekmira Pharmaceuticals|ABUS - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Arbutus Biopharma|ABUS - Book Capitalization|Market Capitalization to Book Value Ratio arbutusbio.com|ABUS - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Arbutus Biopharma|ABUS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Tekmira Pharmaceuticals|ABUS - Company Aggregate Debts|Debts to Book Capitalization Tekmira Pharmaceuticals|ABUS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Arbutus Biopharma|Quick Liquidity arbutusbio.com
- net income and valuation multiples indicators:
ABUS - Net Profit
Fundamental valuation:Arbutus Biopharma
Manufactured products of Arbutus Biopharma

The development of licensing alliances for the transfer of lipid nanoparticle technologies for hepatitis B therapy defines the resource structure of Arbutus Biopharma (ABUS). The total asset value, calculated reverse-engineered via ROA, reflects the balance between equity and liabilities, allowing investors to identify hidden imbalances or the risk of overpaying for a slowing business through gross assets during periods of market optimism.

Key competitors

ARWR - Company Total Asset Base|Aggregate Company Assets Mirum|Dynavax - Total Asset Value of Company|Company Total Assets IVA|GYRE (Gyre Therapeutics Corp.) - Aggregate Asset Value|Company Total Assets ASMB (Assembly Biosciences)|Company Total Assets Galectin Therapeutics, Inc. GALT|GNFT - Aggregate Company Assets|Aggregate Asset Value DRRX (DURECT Corporation)|aligos.com (ALGS) - Aggregate Company Assets|Cumulative Company Assets BioVie|GLMD (Galmed Pharmaceuticals Ltd) - Company Total Assets|Company Total Assets endrainc.com|Cumulative Company Assets HEPA (Hepion Pharmaceuticals)